💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sumatriptan

CHEMBL128 Phase 4 Approuvé Small molecule
Half-Life
2.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
295.4 g/mol
LogP
0.9
Phase
4

Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size. Available in tablet, nasal spray, and injectable forms, it is most effective when taken at the first sign of a migraine.

Masse moléculaire

295,4020 g/mol

LogP

0,90

TPSA

73,60 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pain Management Rheumatoid Arthritis Parkinson's Disease Epilepsy Migraine Multiple Sclerosis Stroke Gout Chronic Pain Cardiovascular Disease

Classes de médicaments

N — N - Nervous System

Mécanisme d'action

Selective 5-HT1B/1D receptor agonist.

Pharmacokinetics (PK)

Half-Life 2.5 hours

Pharmacodynamics (PD)

Mécanisme

Selective 5-HT1B/1D receptor agonist.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H21N3O2S

                    

                    
                    

                        
HBD / HBA

                        
2 / 4

                    

                    
                    

                        
Liaisons Rotatives

                        
6

                    

                    
                    
                    

                        
Atomes Lourds

                        
20

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ADRB2 (Beta-2 Adrenergic Receptor)
                            Agonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            SLC6A4 (Serotonin Transporter)
                            Other
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Sumatriptan + Duloxetine
                            
                        

                        
                        
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Sumatriptan + Sertraline
                            
                        

                        
                        
Sertraline and sumatriptan may interact to increase serotonergic tone, raising the theoretical risk of serotonin syndrome.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Sumatriptan + Escitalopram
                            
                        

                        
                        
Co-administration of escitalopram and sumatriptan may lead to serotonin syndrome, though clinical cases are less frequent than with tramadol combinations.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Sumatriptan + Fluoxetine
                            
                        

                        
                        
Fluoxetine plus sumatriptan may potentiate serotonin syndrome risk, though the clinical evidence is mixed and the absolute risk is debated.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size. Available in tablet, nasal spray, and injectable forms, it is most effective when taken at the first sign of a migraine.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective 5-HT1B/1D receptor agonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Sumatriptan: Half-life: 2.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Sumatriptan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL128.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5358.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.